key: cord-0789735-rzns8mn5
authors: Salzano, Andrea; D'Assante, Roberta; Stagnaro, Francesca Maria; Valente, Valeria; Crisci, Giulia; Giardino, Federica; Arcopinto, Michele; Bossone, Eduardo; Marra, Alberto Maria; Cittadini, Antonio
title: Heart failure management during COVID‐19 outbreak in Italy. Telemedicine experience from a heart failure university tertiary referral centre
date: 2020-05-28
journal: Eur J Heart Fail
DOI: 10.1002/ejhf.1911
sha: 698ac94f38d2384c7fa63ef3b0439cf563aa4b97
doc_id: 789735
cord_uid: rzns8mn5

nan

A few weeks after the first Italian case of person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) 1 , Italian government promulgated a Decree-Law imposing a general lockdown, aimed at reducing the spread of coronavirus disease of 2019 . Among restrictions affecting healthcare system, outpatient clinics and day-services have been suspended, and in-ward access has been granted only for urgent procedures. If on the one hand this reduced the risk of in-hospital COVID-19 spread, on the other hand led to marked decrease in the clinic assistance of chronic diseases -i.e. heart failure (HF).

Aims of the present report were to investigate whether a telemedicine service (TMS), expressly set up by our HF university tertiary referral centre 2 during the COVID-19 outbreak, impacts on HF outcomes (i.e. composite of HF hospitalisation/death), and to compare outcomes with the same period (11 th March -4 th May) of the previous year, when a TMS was not available.

Our TMS included two phone numbers, active 24/7, with the possibility of chat-and videoconference-services available with most popular smartphone applications; an email address was available too. Telemedicine visits were not scheduled, and accesses were all on voluntary basis by the patients, who were advised to use the TMS for all clinical necessity. However, if the attending physician deemed a further access necessary, patients were encouraged to contact us again. All patients were advised to follow all measures to prevent COVID-19 transmission (e.g. social distance, frequent handwashing, the use of face masks in public places, self-isolating). With regard to HF-treatment, we recommended the prosecution of all drugs as medical standard 3 .

Notably, after a few days, European Society of Cardiology published a statement against the discontinuation of ACEi/ARBs/ARNI 4 ; further, recent evidence from literature showed the lack of negative effects of ACEi/ARBs/ARNI for COVID-19 infection and severity 5 . At the end of the study period, all patients were contacted, to get information about outcome. This article is protected by copyright. All rights reserved.

One hundred and three patients participated in the present study; outcomes were compared with data from 104 HF patients attending our unit in the same period of 2019 (Table 1) .

From 11 th March to 4 th May 2020, 58% of patients made at least one TMS access, mostly by phone call (64.2%), followed by chat-service (33.6%). Overall, 51% of contacts led to a clinical decision (adjustment of diuretic doses, change of blood pressure drugs, rate controls, anticoagulants management, others) ( Figure 1 ). With regard to primary outcome, 5 patients experienced the primary endpoint. Specifically, 3 patients were hospitalised (one for NSTEMI-ACS, one for pulmonary oedema, and one for change of defibrillator battery), whereas 2 patients died (both were at terminal stage of HF before the lockdown -NYHA IV-and died for sudden cardiac death).

Notably, none of our HF patients got COVID-19. Pearson's chi square and Fisher exact tests showed that patients in 2019 cohort (when TMS was not available) were more likely than cohort with access to TMS to experienced primary outcome [X 2 (degree of freedom 1, cases = 207) 10 .699, p=0.001]. Specifically, a significant difference was observed for HF hospitalisation (p=0.001) whereas no differences were observed with regard to deaths.

The present investigation represents the first about the utility of telemedicine during the lockdown due to COVID-19 outbreak in Italy; using commonly available technologies (analogic phones, smartphones, apps) our team was able to offer a continuous service for all our HF patients.

It has been described a decrease of acute coronary syndrome-related hospitalisation rates in Italy during the COVID-19 outbreak 6, 7 , suggesting that several patients experienced a poor outcome because they did not access to health system. We provided a TMS that allows our patients to have direct access to health system, observing a significant reduction of primary endpoint when compared to the same period of the previous year, supporting its use to increase the value of health care 8 . Further, our finding supports the recent statement from Heart Failure Society of America, in which the use of the telemedicine for HF management during COVID-19 outbreak is strongly suggested 9 , in line with European Society of Cardiology advice 4 . Notably, recently it has been stated that 'it is a great shame that home telemonitoring was not already routine before the pandemic struck' 10 .

To avoid possible social disparities (e.g. accessibility of service only to people with available technologies and/or capacities to use the service), on purpose we based our telemedicine system mostly on phone calls.

In conclusion, our telemedicine service allows our HF patients to be follow-upped also during COVID-19 lockdown, with a positive impact on HF outcome; the present report confirms telemedicine as a valuable tool in HF-management and shows for the first time its feasibility during COVID-19 outbreak. 

This article is protected by copyright. All rights reserved.

The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

European Society of Cardiology (ESC) Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic

COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease

Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy

Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated with the COVID-19 Outbreak

Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure

Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America

Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic; the advantages of universal-access to home telemonitoring

ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume indexed; LVESVi: left ventricular end-systolic volume indexed; NT-proBNP: amino terminal prohormone b-type natriuretic peptide; ACE-i: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; ARNI: angiotensin receptor neprilysin inhibitor; MRA: mineralocorticoid receptor antagonists. Period of observation: 11 th March-4 th May 2020 for COVID-19 lockdown cohort, and 11 th March-4 th May 2019 for control cohort; * p<0.01; # other interventions: antibiotics management, pain management, general advise. Data expressed as mean ± standard deviation or median

Dr Salzano receives research grant support from CardioPath, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy, and UniNA and Compagnia di San Paolo in the frame of the STAR (Sostegno Teritoriale alla Attività di Ricerca) programme. This article is protected by copyright. All rights reserved.Accepted Article